The majority were published in the United States of America (7/15, 46.67%) followed by Germany (2/15, 13.33%), the United Kingdom (2/15, 13.33%), Sweden, Kuwait, Italy and Colombia (all 1/15, 6.67%)
[1] [2] Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, not a pure GLP-1 agonist
Get the details, including what to look for on supplement labels, in our article about folic acid and folate
Both are GLP-1 receptor agonists used to help manage type 2 diabetes and, in some cases, to support weight loss under medical supervision
If morning dosing does not work with your schedule, evening dosing is an acceptable alternative